T-O (am): 0.000 (08:59:00)
Last updated: 15:08
Customize
Select columns required and click "Update" to save your preferences
EPS | 1.38 sen |
Trailing PE (Sector Median: 26.7) | 17.3 |
PEG | 17.3 |
Altman Z | 1.8 |
Beaver | -0.062 |
Current Ratio | 8.08 |
Debt-Equity (DE) Ratio | 0.24 |
FCF Yield | -1.89 % |
Revenue QoQ | -9.48 % |
Revenue YoY | 25.68% |
Profit QoQ | -26.39 % |
Profit YoY | 0.75 % |
Profit Margin (Sector Median: 8.0) | 15.21 % |
ROE (ROIC: 10.76) | 10.76 % |
Dividend Per Share (DPS) | 0.97 sen |
Dividend Yield (DY) | 4.04 % |
Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports
EPS | |
Trailing PE (Sector Median: 26.7) | |
Profit QoQ | |
Profit YoY | |
Profit Margin (Sector Median: 8.0) | |
ROE (ROIC: 10.76) | |
Altman Z |
Discounted Cash Flow (DCF) 5% Growth | |
Discounted Cash Flow (DCF) 10% Growth | |
Relative Valuation |
Graham Formula | |
Graham Number | |
Net Tangible Asset (NTA) | 0.14 |
Consistent QR FV |
Forward PE FV Calculator | |
Latest Profit (adjusted) [M] | 2.94 |
Expected Profit (Next QR) [M] | |
Expected Profit (After QR above) [M] | |
Expected Profit (After QR above) [M] | |
Estimated Fair Value |
Growth/Risk Fair Value Calculator | |
Expected growth (%) | |
Estimated downside / risk (%) | |
Estimated New DCF Fair Value |
Contract/Award Contribution Calculator | |
Contract/Award Value (in Million) | |
Estimated Contribution to Stock Price | |
Estimated New DCF Fair Value |
Profit-Based Calculator | |
Expected Profit (M) | |
for Year | |
Estimated New DCF Fair Value |
Revenue-Based Calculator | |
Expected Revenue (M) | |
for Year | |
Estimated New DCF Fair Value |
Market Pricing | |
Expected Profit (M) | 0 |
Expected Revenue (M) | 0 |
Expected Growth (%) | 0 |
DR CHONG SU-LIN reduced 100000.0 units announced on 09 Jan 2023 at ~RM0.49
Market Cap: 199 M.
Market Cap Class: Micro caps
Number of Shares: 832 M.
Adjusted Float: 60.2%.
Stock highly correlated with
ECA (95%)
BINACOM (90%)
PRG (90%)
ASTRO (89%)
Cengild Medical Berhad, incorporated in 2021 and headquartered in Kuala Lumpur, Malaysia, specializes in gastrointestinal and liver disease care, with a strong focus on obesity management and related specialties. Operating through its flagship Cengild G.I. Medical Centre, the company offers a wide range of services including gastroenterology, hepatology, gastrointestinal surgery, bariatric surgery, oncology, cardiology, urology, and ENT. It also provides diagnostic imaging, 24-hour emergency care, laboratory services, and outpatient treatments supported by multidisciplinary medical teams. Cengild’s operations are anchored by two main business segments, Consultant Services and Medical Management Services which delivered through state-of-the-art facilities, complemented by satellite primary care clinics under the Poliklinik CGI brand.
Sectors: Healthcare, Health Care Providers, Penny Stocks
Code: 0243
Website: https://www.cengild.com/
Related Links: Bursa | Annual Report | Announcement
No warrants listed
Updated on 2-Oct-2023
Shareholder | % | Value (M) |
---|---|---|
Dato' Dr. Tan Huck Joo | 16.18% | 32.34 |
Anne Marie Loh Foong Han | 9.64% | 19.27 |
Emeritus Professor Dato' Dr Goh Khean Lee | 7.23% | 14.45 |
Dr. Mohamed Akhtar Bin Mohamed Ditali Qureshi | 6.76% | 13.51 |
Tan Kar Tek | 4.83% | 9.66 |
Ramesh A/L K Gurunathan | 4.73% | 9.46 |
Ong Siew Kuen | 3.87% | 7.74 |
Medic Quest Sdn Bhd | 3.48% | 6.96 |
Tony Tan Choon Keat | 3.28% | 6.56 |
Transmetro Sdn Bhd | 2.81% | 5.62 |
Tan Soon Wah | 1.59% | 3.18 |
Tang Vee Mun | 1.57% | 3.14 |
Koon Poh Keong | 1.56% | 3.12 |